China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right

The termination removes a potential source of additional funding and the associated issuance of shares or pre-funded warrants.

Rhea-AI Summary

China SXT Pharmaceuticals (NASDAQ: SXTC) has agreed with purchasers to terminate their additional purchase right under its registered direct offering.

The right allowed purchasers, during the 30-day period following closing, to buy up to an additional $12 million of Class A ordinary shares and/or pre-funded warrants on the offering's terms. The termination fully removes that entitlement under Section 2.4 of the securities purchase agreement for the offering announced October 8, 2026. Securities already issued are unaffected, and all other provisions of the purchase agreement and other transaction documents remain unchanged and in effect.

1 point · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

How the balance works

Positive

• Moderate pointTermination of the additional purchase right removes potential dilution from shares or pre-funded warrants under that right.

Negative

• Moderate pointUp to $12 million in potential additional funding is no longer available through the terminated right. 139× market cap

Argus 15 min delay 79 alerts

+17.76% vs previous close $0.08 last price 52.2x rel. volume Open Argus

Details

Market move: SXTC +17.76% vs previous close. Additional purchase right termination

+19.7% Peak in 6 min

$0.06 – $0.10 Day Range

$101,618 Mkt Cap at Last Price

On Oct 21, the day this news came out, the latest delayed price for SXTC is 17.76% above the previous close. Argus tracked a peak move of +19.7% during the session. Our momentum scanner has recorded 79 alerts for this stock so far that day. The latest delayed price is $0.08. Relative volume is exceptionally heavy at 52.2x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Additional purchase right: Up to $12 million Purchase-right window: 30 days

Additional purchase right

Up to $12 million

Same terms as the offering; the right was terminated

Purchase-right window

30 days

Period following the offering's closing; the right was terminated

Historical Context

1 past event · Latest: Oct 08

1 event

1. Oct 08

   Registered direct offering

   24h Move

   -87.9%

   The offering included a same-terms right to buy up to $12 million within 30 days after closing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, securities purchase agreement, pre-funded warrants

3 terms

registered direct offering financial

"purchasers in its registered direct offering announced on October 8, 2026"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

securities purchase agreement financial

"set forth in Section 2.4 of the securities purchase agreement"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

pre-funded warrants financial

"Class A ordinary shares and/or pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026 (the "Offering").

Under the termination letter agreement, the Company and the purchasers have terminated in full the additional purchase right set forth in Section 2.4 of the securities purchase agreement entered into in connection with the Offering. The terminated right had permitted the purchasers, during the 30-day period following the closing of the Offering, to elect to purchase up to an additional $12 million of Class A ordinary shares and/or pre-funded warrants on the same terms and conditions as the Offering.

As a result of the termination, the purchasers no longer have any right, claim or entitlement to make an additional purchase under Section 2.4 of the securities purchase agreement. All other provisions of the securities purchase agreement and the other transaction documents remain unchanged and in full force and effect. The termination does not affect the securities issued in the Offering.

About China SXT Pharmaceuticals Inc.

Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which are a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.

Forward Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission.

China SXT Pharmaceuticals Inc.

Feng Zhou, Chief Executive Officer
Email: fzhou@sxtchina.com 

View original content:https://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-announces-termination-of-additional-purchase-right-302915380.html

SOURCE China SXT Pharmaceuticals Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What additional purchase right did China SXT Pharmaceuticals terminate?

China SXT terminated purchasers' right to buy up to an additional $12 million of Class A ordinary shares and/or pre-funded warrants. That right could have been exercised during the 30-day period following the offering's closing, on the same terms and conditions as the offering.

Does China SXT's termination affect securities already issued in the offering?

Securities already issued are unaffected by the termination. All other provisions of the securities purchase agreement and the other transaction documents remain unchanged and in full force and effect.